儿童及青年非酒精性脂肪性肝病与长期死亡率增加相关
瑞典全国匹配队列研究纳入718例经活检确诊的非酒精性脂肪性肝病(NAFLD)儿童及青年(≤25岁),匹配3457例一般人群对照。中位随访15.8年,NAFLD患者全因死亡率显著高于对照(aHR 5.88,95%CI 3.77-9.17),20年绝对死亡风险为7.7% vs 1.1%。单纯脂肪变和脂肪性肝炎均与死亡率增加相关, excess死亡主要来自癌症、肝病和心血管代谢疾病。
要点
- 儿童及青年活检确诊NAFLD全因死亡风险为匹配对照的5.88倍。
- NASH患者死亡风险更高(aHR 11.51),单纯脂肪变亦升高(aHR 5.26)。
- 超额死亡主要来自癌症、肝病和心血管代谢疾病。
核心结论
- 瑞典儿童及青年经活检确诊的NAFLD患者全因、癌症、肝病及心血管代谢疾病特异性死亡率显著高于匹配的一般人群对照。
研究设计与样本
- 全国性匹配队列研究,纳入1966-2017年瑞典28个病理科提交的肝活检确诊NAFLD的儿童及青年(≤25岁)718例,按年龄、性别、日历年及县匹配≤5名一般人群对照(n=3457),并另设全同胞对照。
主要发现
- 中位随访15.8年,NAFLD患者死亡59例(5.5/1000人年),对照死亡36例(0.7/1000人年),多变量校正HR 5.88(95%CI 3.77-9.17)。
- NAFLD患者20年全因死亡绝对风险7.7%,对照1.1%,差异6.6%(95%CI 4.0-9.2)。
- 排除最初6个月内死亡者后aHR 4.65(95%CI 2.92-7.42),使用全同胞对照时aHR 11.72(95%CI 3.18-43.23)。
- 单纯脂肪变对比对照的校正死亡率HR 5.26(95%CI 3.05-9.07),NASH为11.51(95%CI 4.77-27.79)。
- 超额死亡主要来自癌症(1.67 vs 0.07/1000人年;aHR 15.60,95%CI 4.97-48.93)、肝病(0.93 vs 0.04/1000人年;aHR 16.46,95%CI 2.75-98.43)和心血管代谢疾病(1.12 vs 0.14/1000人年;aHR 4.32,95%CI 1.73-10.79)。
临床怎么用
- 对儿童及青年NAFLD患者应重视长期随访,关注癌症、肝病及心血管代谢疾病的筛查与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Longitudinal data are scarce regarding the natural history and long-term risk of mortality in children and young adults with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD). METHODS: This nationwide, matched cohort study included all Swedish children and young adults (≤25 years) with biopsy-confirmed NAFLD (1966-2017; n = 718). NAFLD was confirmed histologically from all liver biopsies submitted to Sweden's 28 pathology departments, and further categorized as simple steatosis or steatohepatitis (NASH). Patients with NAFLD were matched to ≤5 general population controls by age, sex, calendar year and county (n = 3,457). To account for shared genetic and early-life factors, we also matched patients with NAFLD to full-sibling comparators. Using Cox regression, we estimated multivariable-adjusted hazard ratios (aHRs) and 95% CIs. RESULTS: Over a median of 15.8 years, 59 patients with NAFLD died (5.5/1,000 person-years [PY]) compared to 36 population controls (0.7/1,000 PY; difference = 4.8/1,000 PY; multivariable aHR 5.88; 95% CI 3.77-9.17), corresponding to 1 additional death per 15 patients with NAFLD, followed for 20 years. The 20-year absolute risk of overall mortality was 7.7% among patients with NAFLD, and 1.1% among controls (difference = 6.6%; 95% CI 4.0-9.2). Findings persisted after excluding those who died within the first 6 months (aHR 4.65; 95% CI 2.92-7.42), and after using full-sibling comparators (aHR 11.72; 95% CI 3.18-43.23). Simple steatosis was associated with a 5.26-fold higher adjusted rate of mortality compared to controls (95% CI 3.05-9.07), and this was amplified with NASH (aHR 11.51, 95% CI 4.77-27.79). Most of the excess mortality was from cancer (1.67 vs. 0.07/1,000PY; aHR 15.60; 95% CI 4.97-48.93), liver disease (0.93 vs. 0.04/1,000PY; aHR 16.46; 95% CI 2.75-98.43) and cardiometabolic disease (1.12 vs. 0.14/1,000PY; aHR 4.32, 95% CI 1.73-10.79). CONCLUSIONS: Swedish children and young adults with biopsy-confirmed NAFLD have significantly higher rates of overall, cancer-, liver- and cardiometabolic-specific mortality compared to matched general population controls. LAY SUMMARY: Currently, the natural history and long-term risk of mortality in children and young adults with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) is unknown. This nationwide cohort study compared the risk of all-cause and cause-specific mortality in pediatric and young adult patients in Sweden with biopsy-confirmed NAFLD to matched general population controls. We found that compared to controls, children and young adults with biopsy-confirmed NAFLD and NASH have significantly higher rates of overall, cancer-, liver- and cardiometabolic-specific mortality.
引用
- Simon TG, Roelstraete B, Hartjes K, et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol. 2021. PMID: 34224779. doi:10.1016/j.jhep.2021.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。